Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion Inc. has demonstrated strong financial performance, evidenced by a 320 basis point increase in adjusted EBITDA margin year-over-year and a 29% growth in adjusted EBITDA to $22.7 million, aligning closely with estimates. The company reported a significant increase in sales, with Preservation Services generating $25.7 million (up 5%) and product sales reaching $87.7 million (up 19%) in the third quarter of 2025. Additionally, Artivion's gross margin improved to 65.6%, exceeding estimates and reflecting a favorable product mix, reinforcing a positive outlook driven by robust revenue growth and margin enhancement.

Bears say

Artivion Inc faces several risks that contribute to a negative outlook, including potential delays in clinical trials and new product approvals, which could hinder future revenue growth. The company’s guidance suggests a concerning trend, with expected revenue growth slowing into the mid- to high-single digits, driven by disappointing new product launches and lackluster international expansion. Furthermore, financial performance has demonstrated inconsistencies, such as the Preservation Services segment missing revenue estimates, highlighting underlying weaknesses in the company's operational efficiency and market demand.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.